Viropro Enters Contractual Partnership With National Research Council-Biotechnology Research Institute
Viropro Inc. (OTC BB:VPRO.OB - News) (``Viropro’’) is pleased to announce that an important contractual partnership has been signed with the National Research Council- Biotechnology Research Institute (NRC-BRI) for the development of one of the company’s main products, a targeted high volume sales Monoclonal Antibody. NRC-BRI has granted Viropro an exclusive worldwide license for cutting edge intellectual property designed to increase the production of specific biopharmaceutical products in manufacturing processes.
The company intends to out-license this product to various biopharmaceutical manufacturing partners. Discussions to this effect are ongoing with a first contract expected to be signed by the end of 2007. Significant revenues are expected between 2008 and 2010 from out-licensing fees and royalties.
``This partnership represents the integration of selected NRC-BRI Intellectual Property and process development expertise to Viropro’s product development. It will minimize the company’s capital expenditure requirements and allow both scientific groups to team-up to advance our core business objectives,’’ said Jean-Marie Dupuy, Viropro’s President and CEO.
Dr. Michel Desrochers of NRC-BRI stated that ``It is with great pleasure that I see one of NRC-BRI’s technology platforms being used to support one of our promising biotech companies.’’
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.